Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter January 23, 2020

Correlation of chemotherapy costs with quality of life in nasopharyngeal cancer patients

  • Achmad Chusnu Romdhoni , Riskha Aulia EMAIL logo , Ririn Prasetyo Utaminingtyas , Suharjono EMAIL logo and Christopher Paul Alderman



Nasopharyngeal cancer (NPC) is the most common neck/head cancer occurring in Indonesia and is the fourth most malignant after breast cancer, cervical cancer, and lung cancer. It is known that the cost of chemotherapy may not be separated from quality of life (QoL) to reflect the success of therapy, especially in cancer patients. Thus, studies on the correlation between chemotherapy cost and the QoL in NPC patients are needed.


The participants were recruited by a consecutive sampling method. All patients diagnosed with NPC using a paclitaxel-cisplatin chemotherapy regimen in August–March 2019 for first until the third chemotherapy cycle were assessed for their the chemotherapy cost and QoL before the first chemotherapy cycle and after the third cycle using the EORTC QLQ-C30 questionnaire. Chemotherapy cost and QoL were analyzed using SPSS version 20 to find out the correlation.


Data from 26 patients showed a notable increase in the QoL after the third chemotherapy cycle. Thus, there was a relationship between chemotherapy cost and QoL in NPC patients. The total cost of chemotherapy increased with the increase in cycles of chemotherapy. We further analyzed the correlation between QoL and the cost of chemotherapy. We found that there was a correlation between the cost and the aspects of global health status, the QoL.


It is concluded that chemotherapy that is followed by the increase in cost in chemotherapy improves the QoL.


The author thanks the Department of Clinical Pharmacy, Faculty of Pharmacy, UniversitasAirlangga and RSUD Dr. Soetomo.

  1. Research funding: This research was funded by Riset Unggulan Perumahsakitan RSUD Dr. Soetomo.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: Research involving human complied with all relevant national regulations and institutional policies. This research has been declared eligible by the ethics committee of Hospital Dr. Soetomo on August 8, 2018 under number 0471/KEPK/VIII/2018.


[1] Dinkes SBY. Prof. Sun Kanker Nasofaring Keganasan yang Tersembunyi. 2018. Available at: in Google Scholar

[2] Kemenkes RI. Panduan Penatalaksanaan Kanker Nasofaring. Jakarta: Kementrian Kesehatan Republik, 2017.Search in Google Scholar

[3] BCCA. Monograph: Cisplatin. BC Cancer Agency Drug Monograph. BC Cancer Agency, 2016;1–11.Search in Google Scholar

[4] BCCA. Monograph: Paclitaxel. BC Cancer Agency Drug Monograph. BC Cancer Agency, 2016;1–10.Search in Google Scholar

[5] Cengiz M, Ozyar E, Esassolak M, Altun M, Akmansu M, Sen M, et al. Assessment of quality life of nasopharyngeal carcinoma patients with EORTC QLQ C30 and H&N 30: Turkish Oncology Group, Head and Neck Working Party Study. Internat J Radiation Oncol 2004;60:558.10.1016/j.ijrobp.2004.07.558Search in Google Scholar

[6] Salehiniya H, Mohammadian M, Hafshejanu M, Mahdaviar N. Nasopharyngeal cancer in the world: epidemiology, incidence, mortality and risk factor. World Cancer Res J 2018;5:1046–53.Search in Google Scholar

[7] Depkes. Deteksi Kanker Leher Rahim dan Kanker Payudara. 2018. Available at: in Google Scholar

[8] Permenkes. Peraturan Menteri Kesehatan Republik Indonesia Nomor 76 Tahun 2016 Tentang Pedoman Indonesian Case Base Groups (INA-CBG’s) dalam Pelaksanaan Jaminan Kesehatan Nasional. Kementrian Kesehatan RI. 2016.Search in Google Scholar

[9] Maniadakis N, Dafni U, Fragoulakis V, Grimani I, Galani E, Fragkoulidi A, et al. Economic evaluation of taxane-based first line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial. Ann Oncol 2009;20:278–85.10.1093/annonc/mdn634Search in Google Scholar PubMed

[10] McCloskey W. Principles of drug literature evaluation dalam Vogenburg, F. R., introduction to applied pharmacoeconomics. New York: McGraw Hill Company, 2001.Search in Google Scholar

[11] Perwitasari DA, Atthobari J, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, et al. Translation and validation of EORTC QLQ-C30 into indonesian version for cancer patients in Indonesia. Jap J Clin Oncol 2011;42:519–29.10.1093/jjco/hyq243Search in Google Scholar PubMed

[12] Wei IW. Nasopharyngeal Cancer. In: Byron B, Johnson, Jonas T, Newlands, Shawn D. Head & neck surgery – otolaryngology, 4th ed. Lippincott, USA: Williams & Wilkins, 2006;35–79.Search in Google Scholar

[13] Adham M, Kurniawan A. Nasopharingeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer 2016;3:185–6.Search in Google Scholar

[14] Chan J, PIlch B, Kuo T, Wenig B, Lee A. Tumours of the nasopharynx. In: Barnes L, EJRPSD, editor. WHO classification of tumours: head and neck tumours. Lyon: IARC Press, 2005:81–106.Search in Google Scholar

[15] Centers for Disease Control. Health-Related Quality of Life. USA; 2016. Available at: Accessed: Dec 2018.Search in Google Scholar

[16] Blond BN, Detyniecki K, Hirrsch K. Assesment of treatment side effects and quality of live in people with epilepsy. Elsevier 2015;15:733–819.Search in Google Scholar

[17] NCCN. Clinical practice guidelines in oncology: head and neck cancers. USA; 2016;1.Search in Google Scholar

[18] Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001;33:350–7.10.3109/07853890109002089Search in Google Scholar PubMed

[19] Brandwein MS. Textbook of head and neck pathology: Volume 1 nose, paranasal sinuses, and nasopharynx. Switzerland: Springer, 2016.10.1007/978-3-319-33323-6Search in Google Scholar

[20] Aaranson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organisation for research and treatment of cancer QLQ-C30: quality of life instrument for use in international clinical trials in oncology. J Nat Cancer Inst 1993;85:365–76.10.1093/jnci/85.5.365Search in Google Scholar PubMed

[21] Saad S, Wang TJ. Nasopharyngeal carcinoma: current treatment options and future directions. J Nasopharyng Carcinoma 2014;16:1–16.Search in Google Scholar

[22] Skrepnek Grant H. Cost-effectiveness analysis. In: Lyle BJ, Townsend Raymond J, McGhan William F, editors. Principles of pharmacoeconomics, 3rd ed. Harvey Whitney Books Company, 1991:120–46.Search in Google Scholar

Received: 2019-08-31
Accepted: 2019-11-18
Published Online: 2020-01-23

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 2.6.2023 from
Scroll to top button